| Address | 16F, Yonsei Severance Bldg., 10, Tongil-ro, Jung-gu, Seoul, Korea (Postal code: 04527) | ||
|---|---|---|---|
| Telephone | 82-10-8711-9554 | Fax | N/A |
| Website | www.bikr.co.kr | junghoon.song@boehringer-ingelheim.com | |
The pharmaceutical company Boehringer Ingelheim was founded in 1885 by Albert Boehringer in Ingelheim. The company has contributed to human health by continuing to research and develop innovate drugs over the past 130 years. Day by day, the 50,000 employees of Boehringer Ingelheim create value through innovation with a clear goal to provide more health and improve the lives of both humans and animals. As part of research and development activities for innovative drugs, the company focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, and oncology. Boehringer Ingelheim Korea was founded in 1976 and creates value through innovation in three business areas: human medicine, animal medicine, and biopharmaceutical consignment production. Among the human pharmaceutical department, anti-cancer drug department is dedicated to shedding light on the unresolved problems of oncology and improving quality of life of patients through steady research based on scientific evidence.
Giotrif is second-generation EGFR TKI lung cancer-targeted anticancer drug that first reimbursed in 2014 by shown long-term treatment effects. Giotrif is a kinase inhibitor indicated as a first-line treatment of patients in metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation. It is also indicated for treatment of patients with metastatic, squamous non-small cell lung cancer (NSCLC) progressing after platinum-based chemotherapy. LUX-Lung 3 & LUX-Lung 6 clinical studies demonstrated statistically significant overall survival improvements over conventional chemotherapy in patients with EGFR positive (Del19 mutation) NSCLC. Also, GioTag study suggested that sequential GIOTRIF and Osimertinib is a feasible treatment option in patients with EGFR mutation-positive NSCLC who subsequently acquire a T790M mutation. The results show that sequential GIOTRIF and Osimertinib conferred encouraging OS and TOT/TTF, especially in patients with a Del19 mutation and Asian ethnicity. Clinical benefit was consistent across all patient subgroups, with particularly encouraging results in patients of Asian ethnicity as well as patients with a Del19 mutation.
